Recent Evidence on Advances in PCI Treatment for Left Main Coronary Artery Disease

Xian Jin; Kaifan Niu; Chengxing Shen

doi:10.31083/j.rcm2311370

Recent Evidence on Advances in PCI Treatment for Left Main Coronary Artery Disease

Rev Cardiovasc Med. 2022 Oct 31;23(11):370. doi: 10.31083/j.rcm2311370. eCollection 2022 Nov.

Authors

Xian Jin¹, Kaifan Niu¹, Chengxing Shen¹

Affiliation

¹ Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 200235 Shanghai, China.

Abstract

Revascularization therapy significantly improves the outcomes of patients with left main coronary artery disease (LMCAD), compared with medical therapy alone. For many years, coronary artery bypass grafting (CABG) has been the primary and standard treatment strategy. However, with advances in percutaneous coronary intervention (PCI) techniques and improvements in patients' outcomes, there is growing evidence supporting PCI for LMCAD. In this review, we aim to integrate the available evidences on advances in PCI treatment for LMCAD and provide guidance for further clinical practice.

Keywords: coronary artery bypass grafting; left main coronary artery disease; percutaneous coronary intervention.

Publication types

Review